UPL Inkomsten in het verleden
Verleden criteriumcontroles 4/6
De winst van UPL is gedaald met een gemiddeld jaarlijks percentage van -30.1%, terwijl de winst van de Chemicals -industrie jaarlijks groeide met 6.7%. De inkomsten zijn groeide met een gemiddeld percentage van 2.2% per jaar. Het rendement op het eigen vermogen UPL bedraagt 5.4% en de nettomarge bedraagt 3.7%.
Belangrijke informatie
-30.10%
Groei van de winst
-30.46%
Groei van de winst per aandeel
| Chemicals Groei van de industrie | 17.68% |
| Inkomstengroei | 2.25% |
| Rendement op eigen vermogen | 5.38% |
| Nettomarge | 3.71% |
| Laatste winstupdate | 31 Mar 2026 |
Recente prestatie-updates uit het verleden
Recent updates
Narratiefupdate • May 18
512070: Upcoming Governance Meetings Will Support Stronger Medium Term Outlook
Analysts have trimmed their price target on UPL from ₹811.50 to ₹776.22, citing revised assumptions around profit margins, a higher future P/E multiple, and updated views on discount rates and revenue growth. What's in the News UPL has scheduled an Analyst/Investor Day, providing an opportunity to hear directly from management about the business and capital allocation plans.
Narratiefupdate • May 01
512070: Fair Pricing Will Depend On Execution Of Upcoming Restructuring And Treasury Plans
Analysts have trimmed their price target on UPL from ₹647.56 to ₹630.00, citing updated assumptions around revenue growth, profit margin, discount rate and future P/E that slightly adjust their valuation framework. What's in the News UPL has scheduled a Special or Extraordinary Shareholders Meeting on March 31, 2026, at 15:30 IST to consider and approve material related party transactions for sale of materials and functional support services between UPL and its subsidiaries, and between Arysta LifeScience Benelux SRL and UPL Europe Supply Chain GmbH (Key Developments).Narratiefupdate • Apr 17
512070: Composite Scheme And Governance Steps Will Support Stronger Medium Term Outlook
Analysts have trimmed their price target on UPL slightly from about ₹820.53 to ₹811.50, reflecting updated assumptions around the discount rate, revenue growth, profit margin and future P/E multiple. What's in the News Board meeting on Feb 20, 2026 to consider a Composite Scheme of Arrangement among UPL Limited and multiple group entities under Sections 230 to 232 and 234 of the Companies Act, 2013, based on recommendations from the Audit Committee and the Committee of Independent Directors (company filing).
Narratiefupdate • Apr 03
512070: Upcoming Governance Decisions And Treasury Scheme Will Support A Stronger Outlook
Analysts have trimmed their price target on UPL from ₹975 to ₹947, citing updated assumptions on long term profit margins and P/E multiples, along with refreshed views on growth, discount rates and fair value. What's in the News UPL has called a Special or Extraordinary Shareholders Meeting for March 31, 2026, at 15:30 IST to seek approval for material related party transactions involving sale of materials and functional support services between UPL and its subsidiaries, and between Arysta LifeScience Benelux SRL and UPL Europe Supply Chain GmbH (Key Developments).Narratiefupdate • Mar 19
512070: Fair Pricing Will Rely On Execution Of Upcoming Restructuring Steps
Analysts have nudged their price target on UPL slightly higher to about ₹648 from roughly ₹641, citing updated assumptions around revenue growth, profit margins, a modestly lower discount rate, and a small adjustment to the expected future P/E multiple. What's in the News UPL has scheduled a board meeting on Feb 02, 2026 at 12:45 Indian Standard Time to consider and approve unaudited consolidated and standalone financial results for the quarter and nine months ended Dec 31, 2025, along with limited review reports from the statutory auditors (Key Developments).Narratiefupdate • Mar 05
512070: Composite Scheme Board Meeting Will Support Stronger Medium Term Outlook
Analysts have raised their price target on UPL by about ₹39 to ₹820, citing updated assumptions that reflect a slightly lower discount rate, a modest tweak to revenue growth and P/E expectations, and a higher projected profit margin. What's in the News Board meeting scheduled for Feb 20, 2026 at 14:30 IST to consider a Composite Scheme of Arrangement involving UPL and its subsidiaries UPL Sustainable Agri Solutions Limited, UPL Global Sustainable Agri Solutions Limited, and UPL Crop Protection Holdings Limited under Sections 230 to 232 and 234 of the Companies Act, 2013 (company filing).Narratiefupdate • Feb 18
512070: Revised Margins And Lower P/E Will Likely Struggle To Support Pricing
Analysts have raised their fair value estimate for UPL from ₹600.67 to ₹641.03, citing updated views on the discount rate, revenue growth, profit margins and future P/E assumptions. What's in the News Board meeting scheduled for Feb 02, 2026, at 12:45 Indian Standard Time to review unaudited consolidated and standalone financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).Narratiefupdate • Feb 04
512070: Higher Margin Assumptions And Upcoming Results Will Support A Stronger Fair Value Outlook
Analysts have raised their fair value estimate for UPL from ₹944 to ₹975, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News UPL has scheduled a board meeting on Feb 02, 2026, at 12:45 Indian Standard Time to review unaudited consolidated and standalone financial results.Narratiefupdate • Jan 21
512070: Higher Revenue And Margin Assumptions Will Support A Stronger Fair Value Outlook
Analysts have raised their fair value estimate for UPL from ₹911.93 to ₹944.00 after updating their assumptions for revenue growth, profit margins, discount rate and future P/E. What's in the News UPL has scheduled a Board Meeting on November 6, 2025 to consider and approve the unaudited consolidated and standalone financial results for the quarter and half year ended September 30, 2025, along with the Limited Review Reports from the statutory auditors (company filing).Narratiefupdate • Jan 07
512070: Small Assumption Tweaks Will Likely Fail To Prevent Margin Pressure
Analysts have slightly increased their fair value estimate for UPL from ₹596.98 to ₹600.67. This reflects small adjustments to assumptions around the discount rate, revenue growth, profit margins and future P/E multiples.Narratiefupdate • Dec 19
512070: Future Margins Will Likely Deteriorate Despite Higher Market Expectations
Analysts have raised their price target for UPL from approximately 526.51 to 596.98, citing slightly stronger expectations for revenue growth and future valuation multiples, partly offset by a more conservative view on profit margins and discount rates. What's in the News UPL Limited has scheduled a board meeting for November 06, 2025 to consider and approve unaudited consolidated and standalone financial results for the quarter and half year ended September 30, 2025, along with the limited review reports from the statutory auditors (company filing).Narratiefupdate • Dec 05
512070: Board Meeting And Stable Assumptions Will Shape Medium Term Outlook
Analysts have modestly raised their price target for UPL to ₹781.39, reflecting slightly improved discount rate and future P E assumptions, while largely maintaining their views on growth and profitability. What's in the News A board meeting is scheduled on November 6, 2025 to consider and approve the unaudited consolidated and standalone financial results for the quarter and half year ended September 30, 2025, along with the Statutory Auditors' limited review reports (company filing).Narratiefupdate • Nov 21
512070: Board Meetings And Adjusted Forecasts Will Influence Medium-Term Outlook
Analysts have raised their price target for UPL from $756.34 to $781.39. This reflects optimism driven by slightly improved revenue growth expectations and adjustments to projected profit margins and valuation multiples.Narratiefupdate • Nov 07
512070: Upcoming Board Decisions And Steady Financials Will Shape Outlook
Analysts have raised their price target for UPL from $736.09 to $756.34. They cite modest improvements in profit margin and revenue growth forecasts as the reason for this adjustment.
Nieuw narratief • Dec 10
Biosolutions Innovation And Improved Financial Stability Expected To Boost Earnings Growth
Strategic inventory management and sales mix enhancement are expected to boost margins and improve earnings.Opbrengsten en kosten
Opbrengsten en kosten
Hoe UPL geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 26 | 518,390 | 19,220 | 65,570 | 0 |
| 31 Dec 25 | 490,770 | 16,210 | 67,060 | 0 |
| 30 Sep 25 | 477,150 | 20,530 | 64,270 | 0 |
| 30 Jun 25 | 467,860 | 10,570 | 63,360 | 0 |
| 31 Mar 25 | 466,370 | 7,610 | 62,460 | 0 |
| 31 Dec 24 | 451,420 | -950 | 58,910 | 0 |
| 30 Sep 24 | 441,220 | -21,400 | 58,950 | 0 |
| 30 Jun 24 | 432,020 | -18,860 | 56,950 | 0 |
| 31 Mar 24 | 430,980 | -13,360 | 55,740 | 0 |
| 31 Dec 23 | 455,890 | -5,830 | 61,940 | 0 |
| 30 Sep 23 | 493,810 | 17,210 | 63,540 | 0 |
| 30 Jun 23 | 517,180 | 27,240 | 63,480 | 0 |
| 31 Mar 23 | 535,760 | 34,350 | 63,220 | 0 |
| 31 Dec 22 | 528,680 | 40,360 | 60,120 | 0 |
| 30 Sep 22 | 504,860 | 38,850 | 58,240 | 0 |
| 30 Jun 22 | 485,460 | 37,050 | 56,780 | 0 |
| 31 Mar 22 | 462,400 | 35,050 | 53,940 | 0 |
| 31 Dec 21 | 431,750 | 32,200 | 47,520 | 0 |
| 30 Sep 21 | 410,040 | 30,780 | 46,110 | 0 |
| 30 Jun 21 | 393,760 | 29,070 | 44,290 | 0 |
| 31 Mar 21 | 386,940 | 27,810 | 43,570 | 0 |
| 31 Dec 20 | 370,390 | 24,250 | 44,650 | 0 |
| 30 Sep 20 | 368,050 | 23,390 | 41,930 | 0 |
| 30 Jun 20 | 356,830 | 20,420 | 34,000 | 0 |
| 31 Mar 20 | 357,560 | 17,760 | 40,910 | 0 |
| 31 Dec 19 | 331,400 | 13,650 | 36,440 | 0 |
| 30 Sep 19 | 291,690 | 9,340 | 34,170 | 0 |
| 30 Jun 19 | 256,090 | 11,150 | 25,020 | 0 |
| 31 Mar 19 | 218,370 | 14,910 | 26,050 | 0 |
| 31 Dec 18 | 190,030 | 19,770 | 22,390 | 0 |
| 30 Sep 18 | 182,760 | 20,900 | 21,600 | 0 |
| 30 Jun 18 | 177,890 | 20,590 | 21,390 | 0 |
| 31 Mar 18 | 173,780 | 20,220 | 20,970 | 0 |
| 31 Dec 17 | 170,290 | 20,270 | 21,470 | 0 |
| 30 Sep 17 | 167,540 | 19,120 | 21,450 | 0 |
| 30 Jun 17 | 165,250 | 18,400 | 20,980 | 0 |
| 31 Mar 17 | 163,120 | 17,270 | 20,610 | 0 |
| 31 Dec 16 | 146,180 | 15,473 | 17,197 | 0 |
| 30 Sep 16 | 140,163 | 13,692 | 16,477 | 0 |
| 30 Jun 16 | 135,366 | 13,840 | 15,884 | 0 |
| 31 Mar 16 | 140,480 | 9,400 | 18,170 | 0 |
| 31 Dec 15 | 125,861 | 11,913 | 23,977 | 37 |
| 30 Sep 15 | 125,370 | 11,538 | 23,595 | 37 |
| 30 Jun 15 | 123,978 | 11,347 | 23,357 | 37 |
Kwaliteitswinsten: 512070 heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (3.7%) 512070 } zijn hoger dan vorig jaar (1.6%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van 512070 is de afgelopen 5 jaar met 30.1% per jaar gedaald.
Versnelling van de groei: De winstgroei van 512070 over het afgelopen jaar ( 152.6% ) overtreft het 5-jarig gemiddelde ( -30.1% per jaar).
Winst versus industrie: De winstgroei 512070 over het afgelopen jaar ( 152.6% ) overtrof de Chemicals -sector 10.1%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 5.4% ) van 512070 wordt als laag beschouwd.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/22 07:34 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
UPL Limited wordt gevolgd door 40 analisten. 16 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| Himanshu Binani | Anand Rathi Shares and Stock Brokers Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |